Published in Nat Rev Gastroenterol Hepatol on August 18, 2015
IBD Cancer and Serious Infection in Europe (I-CARE) | NCT02377258
Biosimilars in IBD: from theory to practice. Nat Rev Gastroenterol Hepatol (2016) 0.91
A Systematic Review of the Cost-Effectiveness of Biologics for the Treatment of Inflammatory Bowel Diseases. PLoS One (2015) 0.86
Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice. J Crohns Colitis (2015) 0.84
Cytokine Networks and T-Cell Subsets in Inflammatory Bowel Diseases. Inflamm Bowel Dis (2016) 0.80
The Th17/Treg Immune Imbalance in Ulcerative Colitis Disease in a Chinese Han Population. Mediators Inflamm (2016) 0.77
Dissociated sterol-based liver X receptor agonists as therapeutics for chronic inflammatory diseases. FASEB J (2016) 0.75
Insights on the use of biosimilars in the treatment of inflammatory bowel disease. World J Gastroenterol (2017) 0.75
Optimizing the Use of Biologic Therapies in the Management of Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y) (2015) 0.75
Development of Monoclonal Antibodies: The Dawn of mAb Rule. Dig Dis Sci (2017) 0.75
Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approach. Clin Exp Gastroenterol (2016) 0.75
Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis. Gut Liver (2016) 0.75
Embracing Complexity beyond Systems Medicine: A New Approach to Chronic Immune Disorders. Front Immunol (2016) 0.75
Trefoil factor-3 is not a useful marker of mucosal healing in Crohn's disease treated with anti-TNF-α antibodies. World J Gastroenterol (2017) 0.75
Schiff base complexes of copper and zinc as potential anti-colitic compounds. Biometals (2017) 0.75
Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases. Dig Dis Sci (2016) 0.75
The Cost-Effectiveness of Vedolizumab for Inflammatory Bowel Disease: A Review of the Current Literature. Gastroenterol Hepatol (N Y) (2016) 0.75
Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease. BMC Med (2017) 0.75
Emerging biologics in inflammatory bowel disease. J Gastroenterol (2016) 0.75
A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease. PLoS One (2017) 0.75
Demystifying the cytokine network: Mathematical models point the way. Cytokine (2016) 0.75
Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease. World J Gastroenterol (2017) 0.75
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
Patients' participation in medical care: effects on blood sugar control and quality of life in diabetes. J Gen Intern Med (1988) 13.57
Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med (2003) 8.49
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis (2010) 6.75
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut (2011) 6.08
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med (2012) 5.80
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med (2006) 5.20
Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol (2010) 5.20
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet (2012) 5.12
Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med (2012) 4.41
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med (2007) 4.39
Management of Crohn's disease in adults. Am J Gastroenterol (2009) 3.94
Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology (2014) 3.77
Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther (2014) 3.74
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis (2012) 3.69
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis (2009) 3.66
Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther (2015) 3.52
Patient participation in deciding breast cancer treatment and subsequent quality of life. Med Decis Making (1997) 3.14
Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA (2011) 2.73
Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol (2009) 2.72
Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet (2014) 2.61
Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut (2011) 2.58
Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis. Gastroenterology (2014) 2.56
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut (2007) 2.53
Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med (2014) 2.04
Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology (2009) 2.00
A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease. Gut (2014) 1.88
Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol (2013) 1.86
Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat (2009) 1.80
Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol (2012) 1.66
Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology (2006) 1.46
Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease. Clin Gastroenterol Hepatol (2013) 1.38
Patient preferences in choosing anti-TNF therapies-R1. Rheumatology (Oxford) (2006) 1.35
A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. Clin Gastroenterol Hepatol (2014) 1.35
Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol (2010) 1.30
Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis (2011) 1.22
Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol (2010) 1.15
A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease. Health Technol Assess (2011) 1.09
Comparative efficacy of biologic therapy in biologic-naïve patients with Crohn disease: a systematic review and network meta-analysis. Mayo Clin Proc (2014) 1.09
Systematic review: Monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD. Gut (2014) 1.09
Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL). Inflamm Bowel Dis (2011) 1.04
Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease. Aliment Pharmacol Ther (2014) 1.01
Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther (2009) 1.01
Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases. Aliment Pharmacol Ther (2013) 0.98
Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease. Aliment Pharmacol Ther (2014) 0.98
An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol (2014) 0.98
Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. Gastroenterology (2014) 0.95
Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol (2013) 0.95
Introducing vedolizumab to clinical practice: who, when, and how? J Crohns Colitis (2015) 0.92
Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease. Inflamm Bowel Dis (2013) 0.89
Economic implications of biological therapies for Crohn's disease: review of infliximab. Pharmacoeconomics (2005) 0.87
Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease. Pharmacoeconomics (2009) 0.87
Ten years of infliximab for Crohn's disease: outcome in 469 patients from 2 tertiary referral centers. Inflamm Bowel Dis (2013) 0.85
Cost-utility analysis of biologic treatments for moderate-to-severe Crohn's disease. Pharmacotherapy (2012) 0.83
Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis. J Gastroenterol Hepatol (2014) 0.83
Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease. Eur J Health Econ (2012) 0.79
CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther (2006) 0.79
Meta-analysis: serious adverse events in Crohn's disease patients treated with TNF-alpha inhibitors. Hepatogastroenterology (2013) 0.79
Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response. J Clin Gastroenterol (2011) 0.79
Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn's disease: a cost-effectiveness analysis. J Crohns Colitis (2012) 0.79